Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pioglitazone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 14/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.98 |
| ▸ | RXRA | P19793 | 1/20 | 0.98 |
| ▸ | MPC2 | O95563 | 1/20 | 0.67 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.54 |
| ▸ | PPARA | Q07869 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pioglitazone SCHEMBL29364546 | 1.00 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL29593116 | 1.00 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL1162440 | 1.00 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL21844 | 1.00 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL4121 | 1.00 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL23534417 | 0.99 | PPARG (0.98) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL2332117 | 0.99 | PPARG (0.98) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL1162192 | 0.99 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL3689044 | 0.99 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL21843 | 0.99 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230266340-A1 | Measurement, Diagnosis, Treatment and Management of Metabolic Syndrome | SILTI AG (CH) | 2023-08-24 | — | — | US | claimed |
| US-20150119327-A1 | DRUG SCREENING PLATFORM FOR RETT SYNDROME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-04-30 | — | — | US | claimed |
| EP-2841067-A2 | A DRUG SCREENING PLATFORM FOR RETT SYNDROME | The Regents of The University of California (US) | 2015-03-04 | — | — | EP | claimed |
| WO-2013163455-A2 | A DRUG SCREENING PLATFORM FOR RETT SYNDROME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-31 | — | — | WO | claimed |
| US-8455523-B2 | Compositions and methods for treating hyperlipidemias | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2013-06-04 | — | — | US | claimed |
| WO-2012158123-A1 | COMPOUNDS AND METHODS FOR TREATING INSULIN RESISTANCE SYNDROME | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2012-11-22 | — | — | WO | claimed |
| US-20120029028-A1 | Compositions and methods for treating hyperlipidemias | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2012-02-02 | — | — | US | claimed |
| EP-1694646-B1 | PROCESS FOR THE SYNTHESIS OF PIOGLITAZONE HYDROGEN CHLORIDE | RICHTER GEDEON VEGYESZET (HU) | 2007-04-25 | — | — | EP | claimed |
| US-20260091038-A1 | COMPOSITIONS AND METHODS FOR ENHANCING WNT SIGNALING FOR TREATING CANCER | MASSACHUSETTS INST TECHNOLOGY (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260071003-A1 | COMPOSITIONS AND METHODS FOR DIRECTING APOLIPOPROTEIN L1 TO INDUCE MAMMALIAN CELL DEATH | UNIV GEORGIA (US) | 2026-03-12 | — | — | US | disclosed |
| US-12486318-B2 | Anti-guanosine antibody as a molecular delivery vehicle | YALE UNIVERSITY (US) | 2025-12-02 | — | — | US | disclosed |
| US-12440497-B2 | Compositions and methods for enhancing Wnt signaling for treating cancer | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250268879-A1 | METHODS OF TREATING NEUROLOGICAL, METABOLIC, AND OTHER DISORDERS USING ENANTIOPURE DEUTERIUM-ENRICHED PIOGLITAZONE | POXEL SA (FR) | 2025-08-28 | — | — | US | disclosed |
| US-20250235415-A1 | MODULATION OF HUMAN BREAST MILK COMPOSITION | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 2025-07-24 | — | — | US | disclosed |
| US-20110053986-A1 | RESPIRATORY DISEASE TREATMENT | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| EP-2222272-A1 | RESPIRATORY DISEASE TREATMENT | Pulmagen Therapeutics (Inflammation) Limited (GB) | 2010-09-01 | — | — | EP | disclosed |
| US-20100184806-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | BRAINCELLS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100184806-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | BRAINCELLS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| WO-2010015818-A1 | RESPIRATORY DISEASE TREATMENT | ARGENTA DISCOVERY LIMITED (GB) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010015818-A1 | RESPIRATORY DISEASE TREATMENT | ARGENTA DISCOVERY LIMITED (GB) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091038-A1 | COMPOSITIONS AND METHODS FOR ENHANCING WNT SIGNALING FOR TREATING CANCER | WNT3A, APC, WNT3 | PPARG 4269/4885CYP3A4 3263/4885RXRA 3453/4885 |
| US-12486318-B2 | Anti-guanosine antibody as a molecular delivery vehicle | SSB, CHMP4B, LAMP2 | PPARG 3861/4885CYP3A4 4677/4885RXRA 3772/4885 |
| US-20100184806-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | PPARG, PPARA, PPARD | PPARG 1/4885CYP3A4 4831/4885RXRA 12/4885 |
| US-20250268879-A1 | METHODS OF TREATING NEUROLOGICAL, METABOLIC, AND OTHER DISORDERS USING ENANTIOPURE DEUTERIUM-ENRICHED PIOGLITAZONE | PPARD, PPARG, PC | PPARG 2/4885CYP3A4 39/4885RXRA 186/4885 |
| US-20260071003-A1 | COMPOSITIONS AND METHODS FOR DIRECTING APOLIPOPROTEIN L1 TO INDUCE MAMMALIAN CELL DEATH | APOL1, APOB, LY96 | PPARG 3516/4885CYP3A4 4152/4885RXRA 1188/4885 |
| US-20150119327-A1 | DRUG SCREENING PLATFORM FOR RETT SYNDROME | GRIN2A, GRIN1, GRIN2B | PPARG 3556/4885CYP3A4 4856/4885RXRA 558/4885 |
| US-12440497-B2 | Compositions and methods for enhancing Wnt signaling for treating cancer | APC, WNT3A, WNT3 | PPARG 4227/4885CYP3A4 4457/4885RXRA 3570/4885 |
| US-20110053986-A1 | RESPIRATORY DISEASE TREATMENT | IL5, PPARD, PPARG | PPARG 3/4885CYP3A4 894/4885RXRA 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.